Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib Combinations in Head and Neck Cancer
NCT00392665Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2006
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of erlotinib in squamous cell carcinoma of the head and neck (HNSCC) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Progression-free Survival at 1 year. Started Oct 2006; status: terminated.
02
Drugs
erlotinib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00392665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00392665.